Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent experience with trazodone.

M Lader1

  • 1Institute of Psychiatry, University of London, UK.

Psychopathology
|January 1, 1987
PubMed
Summary
This summary is machine-generated.

Trazodone is an effective antidepressant and anxiolytic with a favorable side effect profile. It demonstrates low cardiotoxicity and is safer in overdose and better tolerated in elderly patients compared to tricyclic antidepressants.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A patient who changed my practice: Personality disorder or bipolar disorder?

International journal of psychiatry in clinical practice·2014
Same author

Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal.

European psychiatry : the journal of the Association of European Psychiatrists·2012
Same author

Plasma concentrations of tricyclic antidepressive drugs.

British journal of clinical pharmacology·2012
Same author

Caffeine withdrawal symptoms and rate of metabolism.

Journal of psychopharmacology (Oxford, England)·2012
Same author

Buspirone treatment as an aid to benzodiazepine withdrawal.

Journal of psychopharmacology (Oxford, England)·2012
Same author

A comparison of augmenting central serotonin and noradrenaline function in healthy subjects: implications for studies on the neurochemistry of anxiety.

Journal of psychopharmacology (Oxford, England)·2012
Same journal

Tourette syndrome and rage attacks - a longitudinal and cross-sectional study.

Psychopathology·2026
Same journal

Depressing temporal experiences: the COVID-19 Pandemic lockdown in Victoria, Australia.

Psychopathology·2026
Same journal

Involuntary hospitalization for treatment: Triangulation of Perspectives of patients, relatives, and professionals.

Psychopathology·2026
Same journal

Depersonalization, Emotion Embodiment, and Alexithymia in the General Population.

Psychopathology·2026
Same journal

Symptom course in psychiatric and neurodevelopmental diagnostic reasoning: an exploratory vignette-based study.

Psychopathology·2026
Same journal

Operationalizing the Whole of Psychic Life: Toward a Structured Framework for Psychopathology.

Psychopathology·2026
See all related articles

Area of Science:

  • Pharmacology
  • Psychiatry

Background:

  • Trazodone is an atypical antidepressant.
  • It possesses anxiolytic properties.

Purpose of the Study:

  • Review recent European clinical experience with trazodone.
  • Evaluate its efficacy, side effects, and safety profile.

Main Methods:

  • Review of recent European clinical data on trazodone.
  • Assessment of antidepressant efficacy.
  • Evaluation of side effects, including anticholinergic effects.
  • Analysis of anxiolytic actions, cardiotoxicity, and overdosage safety.
  • Examination of use in the elderly population.

Main Results:

  • Trazodone demonstrates efficacy as both an antidepressant and an anxiolytic agent.

Related Experiment Videos

  • The drug exhibits few side effects, notably low anticholinergic burden.
  • Cardiotoxicity is low.
  • Trazodone is safer in cases of overdosage compared to tricyclic antidepressants.
  • It is better tolerated by elderly patients.

    • Conclusions:

    • Trazodone is an effective and well-tolerated treatment for depression and anxiety.
    • Its safety profile, particularly in overdosage and in the elderly, is advantageous.
    • Trazodone represents a favorable alternative to traditional tricyclic antidepressants.